Skip to main content
    C

    Cumberland Pharmaceuticals Inc (CPIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $5.21
    -0.67 (-11.39%)

    Market Cap: $88.16M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Cumberland Pharmaceuticals Inc (CPIX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Cumberland Pharmaceuticals reported revenue of $44.52M for the fiscal year ended Dec 31, 2025, up 17.6% from the year before. That year, net income was -$2.86M with a net margin of -6.4%, operating cash flow was $4.93M and free cash flow was $4.83M. The quarter ended Sep 30, 2026 had revenue of $2.16M and net income of $77.78M.

    Revenue and Margins

    The operating margin was -6.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $33.03M, a compound annual rate of 3.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$44.52M+17.6%85.0%-6.3%-6.4%
    Dec 2024$37.87M-4.3%82.6%-17.0%-17.0%
    Dec 2023$39.55M-5.9%84.7%-24.2%-16.0%
    Dec 2022$42.01M+16.7%78.3%-13.6%-13.4%
    Dec 2021$35.99M-3.9%75.5%-21.3%-10.0%
    Dec 2020$37.44M+8.9%76.9%-17.0%-9.1%
    Dec 2019$34.39M+17.2%78.4%-27.0%-10.3%
    Dec 2018$29.34M-28.7%79.5%-38.1%-24.0%
    Dec 2017$41.15M+24.6%82.1%-9.9%-19.6%
    Dec 2016$33.03MN/A82.0%-4.3%-3.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$44.52M$37.87M$39.55M$42.01M$35.99M$37.44M$34.39M$29.34M$41.15M$33.03M
    Cost of revenue$6.67M$6.59M$6.07M$9.12M$8.81M$8.65M$7.42M$6.02M$7.37M$5.96M
    Gross profit$37.85M$31.28M$33.49M$32.89M$27.17M$28.79M$26.97M$23.33M$33.78M$27.07M
    Research and development$5.57M$4.82M$5.83M$6.69M$5.68M$5.77M$6.87M$7.58M$4.28M$3.19M
    Operating income-$2.79M-$6.43M-$9.55M-$5.70M-$7.68M-$6.38M-$9.29M-$11.17M-$4.08M-$1.43M
    Net income-$2.86M-$6.44M-$6.33M-$5.65M-$3.60M-$3.42M-$3.55M-$7.04M-$8.05M-$1.00M
    EBITDA$2.52M-$123.71K-$118.01K$245.75K-$849.86K-$1.59M-$4.84M-$8.09M-$1.36M$1.05M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.16M$166.46K$9.13M$13.68M$171.82K$380.80K$11.71M$10.44M$9.09M$9.85M$8.50M$9.35M
    Gross profit$2.16M$166.46K$7.20M$11.44M$171.82K$380.80K$10.29M$8.46M$7.76M$8.14M$6.92M$7.82M
    Operating income-$1.94M-$3.16M-$3.13M-$1.37M-$2.86M-$3.12M$1.29M-$1.84M-$1.69M-$1.03M-$1.87M-$6.18M
    Net income$77.78M-$4.27M-$3.29M-$1.43M-$1.95M-$735.21K$1.25M-$1.90M-$1.54M-$1.10M-$1.90M-$6.30M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $5.71M by $5.74M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$76.82M$75.58M$81.78M$92.93M$84.46M$96.46M$104.55M$112.69M$93.23M$93.40M
    Current assets$37.06M$36.45M$35.71M$45.87M$45.69M$49.97M$50.16M$59.12M$68.68M$65.55M
    Cash and equivalents$11.44M$17.96M$18.32M$19.76M$27.04M$24.75M$28.21M$27.94M$45.41M$34.51M
    Total liabilities$52.28M$53.04M$52.52M$56.95M$41.86M$49.59M$53.46M$57.12M$29.31M$20.28M
    Short-term debt$467.77K$5.10M$0$172.91K$969.68K$3.20M$920.43KN/A$9.80M$4.10M
    Long-term debt$5.24M$10.18M$12.78M$16.20M$15.00M$15.00M$18.50M$20.00M$9.80M$4.10M
    Shareholder equity$24.88M$22.85M$29.60M$36.27M$42.81M$46.99M$51.12M$55.84M$64.12M$73.25M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$113.78M$62.88M$71.00M$76.82M$65.90M$67.91M$69.94M$75.58M$76.75M$78.52M$81.51M$81.78M
    Total liabilities$41.60M$45.77M$49.69M$52.28M$40.10M$40.23M$41.60M$53.04M$52.28M$52.49M$54.32M$52.52M
    Cash and equivalents$80.58M$3.86M$11.01M$11.44M$15.20M$16.09M$15.11M$17.96M$17.46M$17.34M$18.55M$18.32M
    Shareholder equity$72.51M$17.44M$21.64M$24.88M$26.12M$27.99M$28.66M$22.85M$24.78M$26.35M$27.49M$29.60M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.0% of operating cash flow. Share repurchases came to 5.5% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$4.93M-$612.19K$6.09M$8.45M$6.34M$5.42M$3.06M$3.11M-$557.71K$569.48K
    Capital expenditures$97.90K$66.46K$281.27K$102.15K$103.53K$140.82K$246.20K$455.57K$275.96K$130.87K
    Free cash flow$4.83M-$678.65K$5.81M$8.35M$6.24M$5.27M$2.81M$2.66M-$833.67K$438.61K
    Dividends paidN/AN/AN/AN/AN/A$135.41KN/A$56.00M$0$0
    Share repurchases$263.48K$579.05K$740.53K$1.05M$1.39M$1.99M$3.49M$3.26M$3.75M$2.52M
    Investing cash flow-$4.71M$57.84K-$105.69K-$13.67M-$501.89K-$1.76M$2.30M-$27.72M$9.51M-$3.12M
    Financing cash flow-$6.75M$196.90K-$7.42M-$2.06M-$3.55M-$7.12M-$5.08M$7.14M$1.95M-$1.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$1.50M$387.02K$3.02K$187.18K$843.80K$3.90M$1.90M$475.50K-$855.66K-$2.14M$1.04M$1.24M
    Capital expenditures$9.81K$0$1$23.79K$26.49K$47.63K$2.28K$15.38K$7.18K$41.62K$48.67K$53.14K
    Free cash flow-$1.51M$387.02K$3.02K$163.39K$817.32K$3.85M$1.90M$460.12K-$862.84K-$2.18M$991.45K$1.18M
    Last 12 quarters

    Frequently Asked Questions About CPIX

    What is Cumberland Pharmaceuticals' annual revenue?

    Cumberland Pharmaceuticals reported revenue of $44.52M for the fiscal year ended Dec 31, 2025.

    How fast is Cumberland Pharmaceuticals' revenue growing?

    Revenue was up 17.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.0%.

    Is Cumberland Pharmaceuticals profitable?

    No. Cumberland Pharmaceuticals reported net income of -$2.86M for the fiscal year ended Dec 31, 2025, with a net margin of -6.4%.

    How much free cash flow does CPIX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $4.93M minus capital expenditures of $97.90K produced free cash flow of $4.83M.

    How much debt does Cumberland Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $5.24M, short-term debt of $467.77K and cash and equivalents of $11.44M.